Replicel Life Sciences Inc. · OTC:REPCF
Replicel Life Sciences — Investor Presentation (November 2015)
26 slides from Replicel Life Sciences's investor presentation, November 2015
Slide 1: Using Cells for Healing
Using Cells for Healing Investor Presentation November 2015
Slide 2: Safe Harbor Statements
Safe Harbor Statements Statements included in this presentation that do not relate to present or historical conditions are “forward looking statements”. Forward-looking statements are projections in respect of future events or our future financial performance. In some cases, you can identify forward
Slide 3: Regenerative Medicine aims to cure instead of treat
Regenerative Medicine aims to cure instead of treat T R E AT M E N T S Regenerative Medicine is defined as “the process of replacing, engineering or regenerating human VS cells, tissues or organs CURES to restore or establish normal function”. “The Social and economic impact of cures versus treatmen
Slide 4: RepliCel Introduction
RepliCel Introduction A regenerative medicine company developing autologous cell therapies Goal: address conditions caused by a deficit of healthy cells required for normal healing and function Current clinical focus: repair chronically injured tendons, restore damaged skin, rejuvenate hair growth P
Slide 5: RepliCel Corporate Overview
RepliCel Corporate Overview First deal (2013): $35M+ deal with Business Model: create high-value assets Shiseido Company for pre-commercial licensing to partners. Next: geographic licensing for tendon, skin & injector device Strategy: minimize overhead, maximize Contract manufacture (Innovacell) R&D
Slide 6: RepliCel Pipeline Overview
RepliCel Pipeline Overview Strong near-term clinical pipeline Indication Product Phase Data Location Chronic tendinosis RCT-01 1/2 2016 Canada Aging and sun damaged skin RCS-01 1 2016 Germany Pattern Baldness RCH-01 2 2018 Germany Pattern Baldness RCH-01 TBD 2017 Japan * * funded by Shiseido Near-te
Slide 7: RepliCel Platform
RepliCel Platform 1. Condition diagnosed 6. Cells injected back into patient using proprietary 2. Biopsy taken from delivery device scalp 5. Cells mixed with carrier 3. Cells isolated from NBDS and frozen hair follicle Fibroblasts (RCT-01, RCS-01) (Wound repair) 4. Cells grow (5-8 weeks) Dermal Shea
Slide 8: RCI-02 Dermal Injector Device
RCI-02 Dermal Injector Device • Prototype build stage • CE mark, 510(k) pathway • Focused licensing program for dermal filler applications 8
Slide 9: RCI-02 Dermal Injector Features
RCI-02 Dermal Injector Features Comfort Grip for Ease of Use • Designed to deliver cells, dermal fillers, drugs and biologics • Digital controls program for Depth, Volume, Rate of dispersion • Provides exact repeatable dispersion across 3 dimensions • Removes human variability • Built-in Peltier ele
Slide 10: Impact of Losing Tendon Function
Impact of Losing Tendon Function the mom who loves to run but has had to stop because of achilles tendinosis the worker no longer able to perform his job because of chronic tendon pain the golfer living with golfer’s elbow who would do almost anything to enjoy a pain-free round
Slide 11: RCT-01 Phase 1/2 Chronic Achilles Tendinosis
RCT-01 Phase 1/2 Chronic Achilles Tendinosis • Active, randomized, double-blinded, placebo-controlled trial at University of British Columbia Sports Medicine Clinic (Canada) • 28 patients, 21 treated & 7 placebo • Primary endpoint - safety through 6 months – Extension study will follow volunteers 18
Slide 12: Predicate Science
Predicate Science Past Clinical: Phase 1 Achilles Tendinosis1 (D. Connell et al., Royal National Orthopaedic Hospital) Function Treatment – Adipose derived dermal fibroblasts • 24 patients (unilateral disease) – 12 treated, 12 controlled – Mean age 45.2 years (20 male, 12 female) – VISA questionnair
Slide 13: Phase 1 Chronic Achilles Tendinosis - 63 Yr-old Male
Phase 1 Chronic Achilles Tendinosis - 63 Yr-old Male • 3-years of chronic pain Ultrasound Image Before Treatment – Day 1 • Failed eccentric loading, casting & platelet rich plasma • Chronic tendinosis: unorganized tissue formation • Pain reduction Ultrasound Image After Treatment – 6 Months • Tendon
Slide 14: Impact of Aging and UV-Damaged Skin
Impact of Aging and UV-Damaged Skin The impact of aging skin may cause depression, social anxiety, lack of confidence and social isolation. “It's more than vanity that drives people's desperation to look good. Your body image accounts for about 1/4 YOUNGER SKIN OLDER SKIN to 1/3 of your self-esteem,
Slide 15: Aging & UV-Damaged Skin
Aging & UV-Damaged Skin • Skin damage caused by aging, UV exposure, lifestyle factors • As we age fibroblasts in the skin produce less collagen causing skin to lose its elasticity and structure Histology YOUNG SKIN Histology OLDER SKIN Collagen Collagen Fibroblast Fibroblast 15
Slide 16: RCS-01 Phase 1 Aging & Sun Damaged Skin
RCS-01 Phase 1 Aging & Sun Damaged Skin RCS-01: NBDS (fibroblast) • Active, randomized, double-blinded, placebo- cells from hair follicle sheath controlled trial at IUF Leibniz-Institut für umweltmedizinische Forschung (Germany) BEFORE • 30 healthy volunteers (24 treated, 6 placebo) • Currently enro
Slide 17: Impact of Hair Loss
Impact of Hair Loss “ I’m a 42 year-old woman suffering from alopecia. I cry myself to sleep at least once a week. ” “ I’m a 24-year old who feels the impact of my baldness on my career and social life on a daily basis. ” 30
Slide 18: Shiseido Partnership – RCH-01 – Asia
Shiseido Partnership – RCH-01 – Asia • Licensing partnership with Shiseido (July 2013) – Geographic license for pattern baldness only for Japan, China, Korea and ASEAN nations – $35 Million ($4M upfront, $31M in sales milestones and royalties) – Shiseido is the 4th largest cosmetic company WW 2013 •
Slide 19: RepliCel Japanese Expedited Approval System
RepliCel Japanese Expedited Approval System Because of regulatory reforms brought into force November 2014, it is now possible to bring a cell therapy product to market faster in Japan than any other regulated country in the world. RepliCel is one of the few foreign companies already positioned in J
Slide 20: Future Potential Therapeutic Applications
Future Potential Therapeutic Applications Potential products from NBDS Platform Periodontal Rotator Cuff Tennis Elbow Golfer’s Elbow Patellar 20
Slide 21: 2015 Accomplishments
2015 Accomplishments Program Event RCT-01 – Tendon Initiate Phase 1/2 trial in chronic Achilles tendinosis RCS-01 – Skin Initiate Phase 1 trial in sun damaged and aging skin RCI-02 – Injector Lock up design specifications Independent Analyst Coverage Initiated (Douglas Loe – Analyst Coverage E
Slide 22: Upcoming Development and Strategic Milestones
Upcoming Development and Strategic Milestones Est. Program Event Timing RCH-01 – Hair Initiate pattern baldness trial (Japan) 2015/6 RCI-02 – Injector CE mark (marketing) approval 1H 2016 RCI-02 – Injector Global license (HA injection) 2016 RCT-01 – Tendon Phase 1/2 data on chronic Achilles tendinos
Slide 23: Pro-Forma Financial Highlights
Pro-Forma Financial Highlights TSXV: RP / OTCQB: REPCF Recent 30-Day Share Price (CDN) $0.29 - $0.38 in $CAD 52 week high/low (CDN) $0.72 - $0.30 Market Cap. (approx.) $17.0 M Total money raised through equity to-date ~16.6M Total revenue to-date $3.8M (initial Shiseido licensing payment) Cash & Equ
Slide 24: Comparable Landscape
Comparable Landscape Exchange Comme Partner COMPANY HQ Price Mkt-Cap (M) Phase Symbol rcial Deals as of Nov. 10, 2015 I II III BioTime NYSEMKT: BTX USA $3.55 $314.75 1 1 Athersys NASDAQ: ATHX USA $1.02 $84.78 1 2 1 Fibrocell Science NYSEMKT: FCSC USA $5.39 $236.62 1 1 1 Ocata Therapeutics Inc. OTCQB
Slide 25: Why Invest? Why Now?
Why Invest? Why Now? TECHNOLOGY - No other cell therapy company: • using cells derived from the hair follicle • in clinical development of a treatment for pattern baldness LOWER RISK - Invest in the regenerative medicine space • lower technical, clinical, and commercial risk than most • lower va
Slide 26: Contact
CONTACT: R. Lee Buckler VP Business Development 604.248.8693 [email protected] OTCQB: REPCF / TSXV: RP
RepliCel Life Sciences — Investor Presentation (November 2015) on 6ix